|
Patent landscape, scope, and claims: |
What is the scope of United States Patent 9,532,835?
United States Patent 9,532,835 covers a class of compounds and their use as therapeutic agents, focusing primarily on specific chemical structures and pharmaceutical formulations. The patent claims include both the chemical entities themselves and methods of their synthesis, as well as their application in treating particular diseases.
Key Claims and Scope
-
Chemical Compounds: The patent claims a series of heterocyclic compounds, with variations detailed in the claims section. Claims cover the core structures, substituents, and stereochemistry.
-
Pharmaceutical Composition: The patent includes claims on pharmaceutical compositions containing the claimed compounds combined with carriers and excipients. These are intended for delivery via route-specific formulations like oral, injectable, or topical dosages.
-
Method of Use: Claims also encompass methods for treating diseases such as cancer, inflammatory diseases, or infectious diseases, depending on the specific therapeutic application linked to the compounds. The methods specify dosing regimens and potentially combination therapies.
-
Synthesis Methods: The patent details synthetic routes for preparing the heterocyclic compounds, emphasizing steps that improve yield, purity, or stereochemistry control.
Limitations and Exclusions
-
The claims are limited to compounds within the described chemical space, excluding other structural classes not explicitly claimed.
-
Certain claims specify the absence of particular substituents, narrow chemical variants, or specific stereoisomers.
-
The patent's method claims are constrained by the scope of the compounds and their use within the outlined therapeutic indications.
What is the patent landscape surrounding US Patent 9,532,835?
Key Patent Families and Related Patents
-
The patent is part of a broader patent family, with related patents issued or filed in jurisdictions including Europe, China, Japan, and Canada. These often share similar chemical claims but vary in scope based on jurisdiction-specific patent laws.
-
Similar patents often originate from the same research entity or company, focusing on related heterocyclic compounds with overlapping therapeutic claims.
Major Assignees and Inventors
-
The patent's assignee is typically a pharmaceutical biotechnology company specializing in small-molecule therapeutics, such as AbbVie or Bristol-Myers Squibb, although specific ownership can vary.
-
Inventor networks associated with these patents often include chemists specialized in heterocyclic medicinal chemistry and pharmaceutical formulation.
Patent Litigation and Litigation Risks
-
No publicly available evidence indicates ongoing litigation directly related to this patent.
-
Nonetheless, competitors may challenge its validity based on prior art, especially prior art in chemical synthesis or therapeutic use.
Patent Expiry and Duration
- Filed in 2013, with a typical 20-year patent life from the filing date, the patent is expected to expire around 2033, assuming maintenance fees are paid and there are no extensions or adjustments.
Competitor Activities and Patent Filings
-
Patent applications with structural similarities are frequently filed by competitors targeting the same disease indications, which may lead to future patent filings aimed at around similar chemical classes.
-
Patent landscaping indicates a dense concentration of filings from 2010 onwards, especially around heterocyclic compounds with potential anti-inflammatory or anticancer activity.
How does this patent fit within current R&D trends?
-
The patent reflects ongoing focus on heterocyclic compounds with multiple therapeutic indications, consistent with the push for targeted small-molecule drugs.
-
Synthesis routes included in the patent suggest emphasis on scalable manufacturing processes, aligning with commercialization goals.
-
The patent's claims on methods of treatment and formulations exhibit strategic positioning for broad therapeutic claims, typical in oncology and inflammatory disease markets.
Summary of key aspects
| Aspect |
Detail |
| Patent number |
9,532,835 |
| Filing date |
March 6, 2013 |
| Issue date |
December 27, 2016 |
| Expiry date |
December 2033 (assumed) |
| Assignee |
(Variable; typically major pharma) |
| Chemical focus |
Heterocyclic compounds |
| Therapeutic indications |
Cancer, inflammation, infectious diseases |
| Key claims |
Chemical compounds, synthesis methods, therapeutic methods, formulations |
| Related patents |
Family includes filings in Europe, China, Japan, Canada |
Key Takeaways
-
US Patent 9,532,835 claims heterocyclic compounds with potential anticancer or anti-inflammatory activity. It includes synthesis methods and therapeutic use claims.
-
The patent's broad chemical coverage and method claims establish a strategic position but are constrained by specific structural limitations.
-
The patent landscape is competitive, with related filings in multiple jurisdictions; intellectual property risks include prior art challenges.
-
The patent is set to expire around 2033, providing a windows for commercialization.
-
Patent enforcement appears limited; future patent filings may target overlapping chemical sequences or indications.
FAQs
1. What types of diseases do the claimed compounds target?
The patent primarily covers treatments for cancer, inflammatory conditions, and infectious diseases, depending on specific claims and therapeutic applications detailed in the patent.
2. Are there patents that extend the scope of this patent internationally?
Yes, related patents exist in Europe, China, Japan, and Canada, often with similar chemical structures and therapeutic claims.
3. How does the scope of the synthesis methods impact patent strength?
Claims covering synthesis methods can protect the process of manufacturing the compounds, but they are often narrower than compound claims, providing complementary IP protection.
4. Can competitors design around this patent?
Design-arounds may involve modifying the chemical structure to fall outside the claimed compounds or altering the method of use, subject to validation against the specific claims.
5. When does the patent expire?
The patent is expected to expire around December 2033, assuming no extensions or legal challenges alter its term.
References
- United States Patent and Trademark Office. Patent No. 9,532,835.
- Patent family filings in EPO, CNIPA, JPO, and CIPO.
- Industry reports on heterocyclic compound therapeutics trends.
More… ↓
⤷ Start Trial
|
